Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

Inclusion Criteria:

1. Age ≥ 18 years

2. Signed informed consent form

3. Suitable for endovascular treatment with VSX based on treating physician's bestmedical judgment

4. Willingness of the patient to adhere to institutional standard of care follow-uprequirements

Exclusion Criteria:

1. Non-compliant lesions where full expansion of an angioplasty balloon catheter is notachievable during pre-dilatation, or where lesions cannot be dilated sufficiently toallow passage of the delivery system.

2. Use of the VSX Device in lesions involving a major side branch that may be coveredby the endoprosthesis.

3. Lesion(s) cannot be treated with available VSX Device sizes per current Instructionsfor Use (IFU).

4. Lesion requires treatment with an altered endoprosthesis or delivery system. (Do notcut the endoprosthesis. The endoprosthesis should only be placed and deployed usingthe supplied catheter system).

5. Previous or concurrent enrollment into this registry (e.g., previous enrollment intoanother treatment cohort or patient requires enrollment into more than one cohort) (Note: Only the first VSX treatment will be enrolled if concurrent VSX proceduresare performed that would require enrollment into more than one cohort).

6. Participation in concurrent research study or registry which may confound registryresults, unless approved by Gore.

7. Known hypersensitivity to heparin or a previous incident of Heparin-InducedThrombocytopenia (HIT) type II.

8. Unable to tolerate antiplatelet therapy.

9. Patient has a non-controllable allergy to contrast or the VSX Device components.

10. Pregnant or breast-feeding female at time of informed consent signature.

11. Life expectancy < 12 months due to comorbidities.

12. Patient has other medical conditions which, as determined by the investigator, mayconfound the data interpretation (e.g., sepsis, thrombophilic diseases, connectivetissue disorders).